Arbutus Biopharma (ABUS) Liabilities and Shareholders Equity (2010 - 2026)

Arbutus Biopharma has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $277.2 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 136.87% year-over-year to $277.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $572.8 million (up 4.29% YoY) and the FY2025 annual result came in at $94.6 million, down 28.16% from the prior year.
• Liabilities and Shareholders Equity improved to $277.2 million in Q1 2026 per ABUS's latest filing, from $94.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $277.2 million in Q1 2026 and troughed at $94.6 million in Q4 2025.
• A 5-year average of $164.4 million and a median of $158.6 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity plunged 35.48% in 2025, then jumped 136.87% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $195.4 million in 2022, then declined by 26.11% to $144.4 million in 2023, then dropped by 8.79% to $131.7 million in 2024, then fell by 28.16% to $94.6 million in 2025, then jumped by 192.93% to $277.2 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $277.2 million, $94.6 million, and $97.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.